CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer

YY Janjigian, J Bendell, E Calvo, JW Kim… - Journal of Clinical …, 2018 - ascopubs.org
Purpose Metastatic esophagogastric cancer treatments after failure of second-line
chemotherapy are limited. Nivolumab demonstrated superior overall survival (OS) versus …
被引用次数：592 相关文章
[HTML] nih.gov

[HTML][HTML] CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer

YY Janjigian, J Bendell, E Calvo, JW Kim… - Journal of Clinical …, 2018 - ncbi.nlm.nih.gov
Purpose Metastatic esophagogastric cancer treatments after failure of second-line
chemotherapy are limited. Nivolumab demonstrated superior overall survival (OS) versus …

CheckMate-032 study: Efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer

YY Janjigian, J Bendell, E Calvo… - Journal of …, 2018 - mdanderson.elsevierpure.com
Purpose Metastatic esophagogastric cancer treatments after failure of second-line
chemotherapy are limited. Nivolumab demonstrated superior overall survival (OS) versus …
[PDF] medpagetoday.com

[PDF][PDF] CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer

YY Janjigian, J Bendell, E Calvo, JW Kim… - J Clin …, 2018 - clf1.medpagetoday.com
Purpose Metastatic esophagogastric cancer treatments after failure of second-line
chemotherapy are limited. Nivolumab demonstrated superior overall survival (OS) versus …

CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer

Y Janjigian, J Bendell, E Calvo, J Kim… - JOURNAL OF …, 2018 - air.unimi.it
Purpose Metastatic esophagogastric cancer treatments after failure of second-line
chemotherapy are limited. Nivolumab demonstrated superior overall survival (OS) versus …
[HTML] europepmc.org

[HTML][HTML] CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.

YY Janjigian, J Bendell, E Calvo, JW Kim… - Journal of Clinical …, 2018 - europepmc.org
Purpose Metastatic esophagogastric cancer treatments after failure of second-line
chemotherapy are limited. Nivolumab demonstrated superior overall survival (OS) versus …
[PDF] core.ac.uk

[PDF][PDF] CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer

YY Janjigian, J Bendell, E Calvo, JW Kim, PA Ascierto… - J Clin Oncol, 2018 - core.ac.uk
Purpose Metastatic esophagogastric cancer treatments after failure of second-line
chemotherapy are limited. Nivolumab demonstrated superior overall survival (OS) versus …

CheckMate-032 study: Efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer

YY Janjigian, J Bendell, E Calvo… - Journal of Clinical …, 2018 - pure.johnshopkins.edu
Purpose Metastatic esophagogastric cancer treatments after failure of second-line
chemotherapy are limited. Nivolumab demonstrated superior overall survival (OS) versus …
[PDF] semanticscholar.org

[PDF][PDF] CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer

YY Janjigian, J Bendell, E Calvo, JW Kim… - J Clin …, 2018 - pdfs.semanticscholar.org
Purpose Metastatic esophagogastric cancer treatments after failure of second-line
chemotherapy are limited. Nivolumab demonstrated superior overall survival (OS) versus …

CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer

YY Janjigian, J Bendell, E Calvo, JW Kim… - Journal of Clinical …, 2018 - eprints.gla.ac.uk
Purpose: Metastatic esophagogastric cancer treatments after failure of second-line
chemotherapy are limited. Nivolumab demonstrated superior overall survival (OS) versus …